Katerina Akassoglou, PhD, senior investigator at Gladstone Institutes, has been named a fellow of the National Academy of Inventors (NAI). Election to NAI is the highest professional distinction given solely to academic inventors.
“Election to the NAI further encourages us to pursue challenging problems in biology and medicine to develop urgently needed treatments for devastating human diseases.”
Dr. Katerina Akassoglou, named one of the Most Influential Women in Bay Area Business. To view the full article, click here.
Study by the Akassoglou Lab showed that blocking a particular receptor protein of the BMP signaling pathway, effectively promoted the maturation of myelin-producing cells and myelin repair. To read the full article, click here.
Members of Akassoglou Lab working on a new study for new line of drugs to potentially stimulate myelin repair in the presence of toxic blood leaks in the brain. To view the full article, click here.
Illustration by Ella Marushchenko
The Akassoglou Lab showed toxic blood leaks in the brain inhibiting remyelination with implications for the development of therapeutic strategies for neuro-repair in multiple sclerosis and other neurological diseases with blood-brain barrier disruption and myelin damage. From Petersen et al. BMP receptor blockade overcomes extrinsic inhibition of remyelination and restores neurovascular homeostasis. Pp. 2291-2301.
Barancik Prize winner Katerina Akassoglou, PhD, studies links between the brain, immune system, and blood-brain barrier.
Click here to view complete article.
Scientists at Akassoglou Lab identifying toxic elements that inhibit repair of damaged myelin and producing studies to find new treatments. To view full article click here.
Since 1985, the Alzheimer’s Disease Research (ADR) program has awarded nearly $140 million to support promising research in fields ranging from molecular biology to genetics to epidemiology. ADR is currently supporting 133 outstanding biomedical researcher projects.
A small team of scientists at the Akassoglou Lab is working on what could be a big breakthrough in treating dementia and other brain diseases. To read full article , click here.
Therini Bio announced raising $17 million in a financing round to speed the development of an antibody that might treat people with inflammatory conditions, such as multiple sclerosis (MS), associated with damage to blood vessels. To read full article, click here.
